Chief Scientific Officer
Chief Medical Officer

Zelluna Immunotherapy AS is a privately owned Norwegian biopharmaceutical company founded in 2016 focused on the development of TCR based immunotherapies targeting a broad range of solid cancers with a high unmet medical need. In November 2017 Zelluna announced the appointment of Miguel Forte as Chief Executive Officer.  One of Miguel’s key objectives is to lead Zelluna through its next stage of development by driving clinical translation of the TCR pipeline, developing new international scientific and commercial partnerships and forging relationships with the international investor communities.

To assist Miguel in driving the business forward he engaged Tom Bradley and Stuart Penney to undertake two business critical searches for a Chief Scientific Officer and a Chief Medical Officer. Having successfully completed these assignments with outstanding candidates from the UK and Germany respectively the incumbents will be an integral part of the executive leadership team and will be pivotal in strengthening the quality and progress of Zelluna’s pipeline focusing on providing crucial scientific, clinical and translational medicine input to early stage R&D projects.

“Tom and Stuart’s network, energy and focus were instrumental for the success in the CSO and CMO appointments. Their understanding of Zelluna’s business priorities and vision together with their constant availability made the executive search process very effective and a real pleasure!”

Miguel Forte, Chief Executive Officer, Zelluna

Miguel Forte